Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brox CZ is a pharmaceutical liquid formulation distributed by Rax Health Care, an Indian pharmaceutical wholesaler and trader. The product is available in multiple forms, including oral syrups and drops, intended for the management of respiratory and allergic conditions. While the specific composition is not explicitly detailed in the distributor's catalog, the 'Brox' prefix in the Indian market typically signifies the presence of **ambroxol**, a mucolytic agent that thins and loosens mucus in the airways to facilitate expectoration. The 'CZ' suffix commonly indicates the inclusion of **cetirizine**, a second-generation H1-antihistamine used to alleviate symptoms of allergic rhinitis and chronic urticaria, such as sneezing, itching, and runny nose. Depending on the specific product form, it is administered either orally as a syrup or topically as drops (e.g., nasal application).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Brox CZ.